Calcium and Vitamin D Tablets Australia: Why the Complete Bone Health Protocol Requires D3, K2, and Calcium Together

Australia presents a paradox that should not exist: one of the highest UV-index environments on the planet, and yet data from the Australian Bureau of Statistics confirms that approximately one in four Australian adults remains Vitamin D deficient — with that proportion rising to over one in three during the winter months in southern states. The explanation lies not in the sun but in how Australians interact with it: indoor professional lifestyles, mandatory sunscreen use, and sun-protective clothing suppress endogenous Vitamin D synthesis to the point where millions of people living in one of the world's sunniest countries are running a clinically significant Vitamin D deficit. The downstream consequence for skeletal health is direct: without adequate Vitamin D3, the intestinal absorption of calcium through active transport mechanisms drops dramatically, and the body compensates by extracting calcium from its own structural reserve — your bones.

Understanding calcium and vitamin D tablets properly means going beyond the basic narrative of "calcium builds bones, D helps absorb it." The science has moved significantly further. The critical missing piece in most bone health supplement protocols is Vitamin K2 — specifically the MK-7 form at the dose examined by the Knapen 2013 randomised controlled trial in Osteoporosis International. Without K2, absorbed calcium lacks the regulatory direction that determines whether it deposits in bone matrix or soft tissue. This distinction — the "calcium paradox" — is why the most well-designed calcium and vitamin D tablets protocol is not a two-nutrient system but a three-nutrient system, and why the published evidence for Vitamin D3 combined with MK-7 K2 is among the most compelling in the skeletal health nutrition literature. This guide explains the full system, the evidence behind it, and how to build a daily routine that genuinely supports your bone density across the life stages where it matters most. Always read the label and follow the directions for use. If symptoms persist, talk to your health professional.

The Australian Sunlight Paradox and What It Means for Your Bones

Vitamin D3 — cholecalciferol — is synthesised in the skin through the action of UVB radiation on 7-dehydrocholesterol. In theory, Australia's UV environment should make deficiency vanishable. In practice, the combination of indoor work schedules, the Cancer Council's evidence-based sun protection guidelines, the reduced synthetic efficiency of melanin-rich skin, and the dramatic decline in skin synthesis efficiency with age (estimated at 75 percent less efficient in a 70-year-old compared to a 25-year-old) creates a population-level Vitamin D insufficiency that the Australian sun alone cannot resolve. For the millions of Australians whose serum 25-hydroxyvitamin D falls below the 50 nmol/L sufficiency threshold, the consequences for skeletal health are direct and progressive.

Vitamin D3 is the primary regulator of calcium absorption in the small intestine. It travels to the nuclei of intestinal enterocytes, where it activates the transcription of calbindin, the calcium-binding protein responsible for active transport of calcium across the intestinal wall into systemic circulation. When Vitamin D3 levels are sufficient, active transport operates at high efficiency and the body can absorb 30 to 40 percent of ingested calcium. When Vitamin D3 is deficient, active transport is reduced, and the body reverts to passive diffusion — an absorption mechanism that captures as little as 10 per cent of dietary calcium regardless of intake volume. This is the physiological mechanism that makes Vitamin D insufficiency a direct skeletal nutritional concern: the calcium on your plate becomes largely inaccessible to your bones, and the body compensates through resorption — extracting stored calcium from the skeletal reservoir to maintain the serum concentrations required for cardiac and neuromuscular function.

Why Supplementation Is a Nutritional Necessity, Not a Lifestyle Choice

For the Vitamin D-insufficient adult — and the ABS data suggests this describes a substantial proportion of the Australian population — dietary calcium at any intake level may not produce optimal skeletal outcomes without concurrent Vitamin D3 supplementation to support the active transport mechanism. This is why calcium and vitamin D tablets have a genuine nutritional rationale that goes beyond supplementation as a wellness trend: they address a measurable, physiologically consequential gap in the specific mechanism that governs how much of your dietary calcium actually reaches your bones. To map your specific Vitamin D status and skeletal support needs against your life stage and lifestyle profile, take the Zenutri personalised health quiz before selecting your formulation pathway. Vitamin and mineral supplements can only be of assistance if dietary intake is inadequate.

Life Stage and the Shifting Skeletal Stakes

Bone mineral density follows a predictable arc across the lifespan. Peak bone mass is reached in the late 20s to early 30s, after which a slow but steady net resorption process begins. In women, the rate of bone density loss accelerates sharply in the years around menopause as declining oestrogen removes its protective effect on osteoclast activity — the cellular mechanism responsible for bone resorption. The Australian Institute of Health and Welfare estimates that osteoporosis affects approximately one million Australians, with one in two women and one in three men over 60 experiencing an osteoporotic fracture during their lifetime. The most effective nutritional intervention is not reactive — it is the sustained maintenance of adequate D3, K2, and calcium across the decades before bone density loss becomes clinically apparent. The time to invest in your skeletal nutritional protocol is before fragility, not after it.

The Three-Nutrient System: D3, K2, and Calcium

The conventional framing of calcium and vitamin D tablets as a two-nutrient system is nutritionally incomplete. The evidence base for bone health nutrition has established a third element — Vitamin K2 in its MK-7 form — as an important component of any serious skeletal support protocol. Understanding the distinct biological role of each nutrient and how they interact biochemically clarifies why omitting any one of them creates a partial solution.

Vitamin D3 is the gatekeeper for calcium entry: it governs how much calcium crosses from the intestinal lumen into the bloodstream. Calcium is the structural substrate: the mineral that is incorporated into the hydroxyapatite crystal matrix of bone tissue. Vitamin K2 is the regulatory director: it activates the two calcium-regulating proteins that influence where absorbed calcium is deposited in the body. Without K2, calcium that has been absorbed under the influence of D3 lacks biochemical direction — it may deposit in bone matrix, or it may deposit in soft tissue. The Geleijnse 2004 prospective study found associations between higher dietary Vitamin K2 intake and general cardiovascular health maintenance — an outcome attributed to K2's role in activating matrix Gla protein (MGP), which supports healthy calcium distribution in arterial tissue. This research is provided as general educational information about the ingredient; the TGA-permitted indication for Osteo+Core (AUST L 520792) is: "Vitamin D helps calcium absorption and a diet deficient in calcium can lead to osteoporosis in later life."

Osteocalcin and Matrix Gla Protein: The K2-Dependent Proteins

Two calcium-regulatory proteins are directly dependent on Vitamin K2 for their activation. Osteocalcin is synthesised by osteoblasts — the bone-forming cells — and requires carboxylation by Vitamin K2 to achieve its active conformation. In its activated form, osteocalcin helps bind calcium ions from circulation and incorporate them into the hydroxyapatite crystal lattice of bone matrix. In the absence of adequate K2, osteocalcin remains undercarboxylated and less functional, meaning the calcium absorbed under D3's influence may not be efficiently mineralised into bone regardless of how much is present in circulation. Matrix Gla protein (MGP), similarly K2-dependent, is expressed in arterial smooth muscle cells and cartilage, where it supports healthy calcium distribution in vascular tissue. A nutritionally complete calcium and vitamin D tablet protocol addresses this by providing K2 at the research-informed dose identified in published studies as sufficient to support activation of both proteins.

The MK-4 vs. MK-7 Distinction

Not all Vitamin K2 forms are nutritionally equivalent. MK-4 (menaquinone-4) has a short half-life in circulation — measured in hours — and requires multiple daily dosing at high doses (typically 45mg three times daily, as used in Japanese clinical trials) to maintain tissue concentrations. MK-7 (menaquinone-7), derived from the fermented soy food natto, has a half-life of 72 hours or more in human circulation, enabling once-daily dosing at much lower doses to maintain sustained tissue concentrations. The Knapen 2013 three-year RCT used 180mcg of MK-7 daily — a dose achievable in a single capsule, sustained across 24-hour tissue activity, and associated with the bone density outcomes that make MK-7 the preferred K2 form for once-daily supplement protocols. Zenutri's Osteo+Core (AUST L 520792) provides D3 at 25mcg (1,000 IU) alongside MK-7 K2 at exactly 180mcg — the dose the Knapen trial examined.

The Published Evidence Behind Vitamin K2 and Bone Health

The published case for Vitamin K2 supplementation in bone health is grounded in two landmark studies that together support both the skeletal and general cardiovascular health rationale for including MK-7 in any serious calcium and vitamin D tablets protocol.

The Knapen 2013 MK-7 Bone Density RCT

Published in Osteoporosis International in 2013, the Knapen randomised controlled trial enrolled 244 healthy postmenopausal women and compared daily MK-7 supplementation at 180mcg against placebo over three years. The primary outcomes were bone mineral density and bone strength indices — the most meaningful measures of skeletal health in a population at highest risk of osteoporotic fracture. The MK-7 group demonstrated significantly improved bone mineral density at the lumbar spine and femoral neck, reduced levels of undercarboxylated osteocalcin (confirming functional K2 activity at the cellular level), and superior bone strength index scores compared to placebo. This is the foundational published evidence for 180mcg of MK-7 as the research-informed dose in bone health supplementation — and it is the dose that Zenutri's Osteo+Core (AUST L 520792) is formulated to provide.

The Geleijnse 2004 Dietary K2 and Cardiovascular Health Study

Published in the Journal of the American College of Cardiology, the Geleijnse 2004 prospective cohort study analysed data from the Rotterdam Heart Study and examined the relationship between dietary Vitamin K2 intake and cardiovascular outcomes. Participants with higher dietary Vitamin K2 intake showed associations with general cardiovascular health maintenance and lower rates of severe aortic calcification — an outcome attributed to K2's activation of matrix Gla protein in arterial tissue. Vitamin K1 intake showed no such relationship — suggesting the association was specific to K2's role in MGP activation. This research is provided for general educational purposes about Vitamin K2 as an ingredient. For individuals who take calcium and vitamin D tablets to support skeletal health, this study provides additional context for ensuring a K2 component is present in the protocol, supporting healthy calcium distribution rather than just calcium absorption.

Vitamin D3 Dose and the 1,000 IU Foundation

The NHMRC 2017 Nutrient Reference Values establish an Adequate Intake of 600 IU of Vitamin D3 for Australian adults under 70, rising to 800 IU for those over 70. However, these values represent sufficiency thresholds for populations with average sun exposure — not targets for the indoor-working, sun-avoiding Australian adult whose serum 25-hydroxyvitamin D is already insufficient. Most clinical guidance for Vitamin D supplementation in insufficient adults suggests 1,000 IU as a safe, effective daily dose to support serum levels above the 50 nmol/L sufficiency threshold without approaching the 4,000 IU safe upper limit established by the NHMRC. At 1,000 IU (25mcg), Osteo+Core provides a foundation dose appropriate for most Australian adults supplementing in the context of assessed or likely insufficiency — and one that can be safely combined with modest dietary Vitamin D from oily fish and fortified foods without risk of excess accumulation.

Dietary Calcium vs. Supplements: Bridging the Gap

The NHMRC 2017 Nutrient Reference Values recommend 1,000mg of calcium daily for Australian adults under 50, rising to 1,300mg for women over 50 and all adults over 70 — the life stages at which bone resorption rates accelerate and the skeletal buffer is being drawn down most rapidly. Meeting these targets through diet alone is achievable in principle but difficult in practice, particularly for the significant proportion of Australian adults who avoid or limit dairy, have lactose intolerance, or follow plant-based dietary patterns.

A 200ml glass of full-fat dairy milk provides approximately 240mg of calcium. A 150g tub of Greek yoghurt provides approximately 200mg. Half a cup of firm tofu set with calcium sulphate provides approximately 250mg. One hundred grams of canned salmon with bones provides approximately 200mg. Reaching 1,000mg through these sources alone requires consistent, deliberate dietary planning — and even when achieved on paper, the bioavailability of dietary calcium is significantly affected by two dietary compounds concentrated in many of the plant foods that appear most prominently in healthy Australian diets.

Oxalates and Phytates: The Hidden Calcium Inhibitors

Oxalic acid, found at high concentrations in spinach, silver beet, and beetroot greens, binds calcium in the intestinal lumen to form insoluble calcium oxalate. This compound cannot be absorbed and is excreted. The bioavailability of calcium from raw spinach is estimated at less than 5 percent, compared to approximately 32 percent from dairy milk and approximately 21 percent from fortified soy milk. Phytic acid, concentrated in whole grains, legumes, and seeds, similarly chelates calcium (and zinc and iron) in the gut, reducing absorption. These anti-nutrient effects are partially mitigated by cooking, soaking, fermenting, and sprouting — but not eliminated. The practical consequence is that plant-rich diets, while providing calcium on a food composition label, deliver substantially less bioavailable calcium to the bloodstream than the label figures suggest. Quality calcium and vitamin D tablets provide calcium in standardised forms — primarily calcium carbonate (best absorbed with food) or calcium citrate (absorbed without food, preferable for those with reduced stomach acid) — that are not subject to the oxalate and phytate interference that reduces dietary calcium bioavailability from plant sources.

Calcium Absorption Efficiency and the Case for Divided Dosing

The intestinal active transport mechanism for calcium operates with declining efficiency at higher single doses. Research consistently shows that calcium absorption is maximised at doses of 500mg or less per ingestion event — above this threshold, the saturable transport system is overwhelmed and an increasing proportion of the ingested dose relies on the far less efficient passive diffusion pathway. For individuals targeting 1,000 to 1,300mg daily from supplemental sources, splitting the dose into two ingestion events separated by several hours yields meaningfully higher absorbed calcium compared to a single large-dose supplement. This is a practical optimisation directly relevant to anyone selecting calcium and vitamin D tablets: a single 1,200mg calcium tablet taken at breakfast is likely to deliver less absorbed calcium than two 600mg doses taken with breakfast and dinner respectively.

The Calcium-Magnesium Competitive Interaction

High-dose calcium and magnesium compete for shared intestinal transport channels when ingested simultaneously — a competitive interaction directly relevant to anyone running a combined bone-health and general nervous-system nutritional protocol. The practical management is straightforward: avoid taking large-dose calcium supplements at the same meal as magnesium supplementation, and maintain a two-hour separation between calcium intake and iron supplementation (non-haem iron and calcium compete for the divalent metal transporter). Consistent with the Zenutri supplement series framework, these interaction considerations are built into the formulation design — Osteo+Core (AUST L 520792) provides D3 and K2 without calcium, allowing the calcium component to be timed separately from any magnesium-containing formulation in a combined protocol.

The Zenutri Bone Health Protocol: Precision, Synergy, and Daily Practice

Zenutri's approach to bone health supplementation begins with the published evidence and works backward to the formulation. Osteo+Core (AUST L 520792) was formulated around two landmark datasets: the Knapen 2013 MK-7 bone RCT that examined 180mcg of MK-7 for bone mineral density outcomes, and the Geleijnse 2004 dietary K2 study that established associations between K2 intake and general cardiovascular health maintenance. The D3 dose of 1,000 IU (25mcg) reflects clinical guidance for Vitamin D supplementation in the context of likely Vitamin D insufficiency among Australian adults. Every number on the label is a formulation decision informed by published research, not a manufacturing convenience.

All Zenutri formulations carry TGA AUST L listings, confirming Australian manufacture under current Good Manufacturing Practice standards and verified label accuracy. The TGA assesses listed medicines for safety and manufacturing quality; it does not individually assess them for efficacy. Within the broader Zenutri longevity protocol, Osteo+Core sits alongside Reversa NR, UbiQ Forte, and CurcuNova in the Zenutri Daily Foundation Bundle — a four-pathway system that addresses skeletal health as one dimension of a comprehensive healthy ageing nutritional protocol rather than an isolated concern. Mandatory warning for Osteo+Core: Vitamin K may interact with anticoagulant medications including warfarin. Consult your GP before use if taking anticoagulant medications.

Timing, Fat Co-Administration, and the Bone Health Routine

Both D3 and K2 are fat-soluble vitamins. Their intestinal absorption requires dietary lipids to trigger bile salt secretion and activate the micellar transport mechanism that carries fat-soluble nutrients across the intestinal wall. Taking Osteo+Core with a fat-free meal or on an empty stomach will measurably reduce the absorption of both active ingredients. The practical requirement is a meal containing at least 10 to 15 grams of healthy fat — eggs, avocado, olive oil, full-fat dairy, oily fish, or a small handful of nuts all qualify. In studies where Vitamin D3 was taken with a fat-containing meal versus a fat-free meal, blood 25-hydroxyvitamin D levels were measurably higher in the fat co-administration group. Place your Zenutri daily sachet next to your morning coffee machine or breakfast prep area to create a habit-stacking anchor that makes this timing automatic rather than deliberate.

The 90-Day Skeletal Health Framework

Bone mineralisation operates on a timeline governed by the osteoblast-osteoclast remodelling cycle. Changes in bone mineral density are not perceptible in days or weeks; they require sustained nutritional support across months and are measurable in clinical trials primarily through DEXA scans at 6 to 12-month intervals. The Knapen 2013 trial was conducted over three years, reflecting the timeline required for meaningful structural bone changes.

For the 90-day assessment window consistent with this series, track two functional proxies that respond faster than structural bone density: subjective muscle cramp frequency (calcium and magnesium nutritional sufficiency indicator) and general energy levels on waking (Vitamin D nutritional sufficiency indicator, given D3's role in muscle function and general fatigue support). These markers typically show improvement within 30 to 60 days of consistent D3 supplementation in previously insufficient individuals. The structural skeletal benefit requires the longer commitment, but these functional signals confirm the protocol is operating as intended in the interim. At the 90-day mark, return to the Zenutri health quiz to ensure your protocol remains calibrated to your current life stage and health profile.

Invest in Your Skeletal Nutritional Foundation Before Fragility Demands It

The most important thing to understand about calcium and vitamin D tablets is that the two-nutrient framing is incomplete. Vitamin D3 governs the entry of calcium into circulation; Vitamin K2 at 180mcg MK-7 influences where that calcium goes once it is there. Without the K2 component, absorbed calcium lacks the biochemical direction that osteocalcin and MGP activation provides. With K2 at the Knapen-examined dose, absorbed calcium is directed by activated osteocalcin toward bone matrix and supported in healthy vascular calcium distribution by activated MGP. This is the difference between a supplement that partially addresses skeletal health and one that more completely supports it.

Zenutri's Osteo+Core (AUST L 520792) provides D3 at 1,000 IU and MK-7 K2 at 180mcg — both nutrients at the doses that the most rigorous published human evidence has examined, manufactured in Australia to TGA cGMP standards, and available in the daily sachet format that makes the consistency skeletal health requires structurally achievable. The bones you have at 65 are largely the product of the nutritional decisions you make in the decades before. The investment in a complete, evidence-informed bone health nutritional protocol is most valuable when made before the deficit is visible — not after it has progressed to fragility.

Ready to build a bone health nutritional protocol grounded in published evidence rather than label claims? Take the free Zenutri health quiz for your personalised skeletal support recommendation.

Vitamin and mineral supplements can only be of assistance if dietary intake is inadequate and should not replace a balanced diet. Always read the label and follow the directions for use. If symptoms persist, talk to your health professional.

Frequently Asked Questions

Should I take calcium and Vitamin D tablets together, and do I also need Vitamin K2?

Calcium and Vitamin D3 should always be taken together — D3 is the nutritional requirement for active calcium transport across the intestinal wall, without which a significant proportion of dietary and supplemental calcium may not be absorbed. The more complete nutritional protocol adds Vitamin K2 as a third component. K2 activates two calcium-regulating proteins — osteocalcin (which supports calcium incorporation into bone matrix) and matrix Gla protein (which supports healthy calcium distribution in arterial tissue). The Knapen 2013 RCT examined 180mcg of MK-7 K2 for bone mineral density outcomes over three years; the Geleijnse 2004 study examined associations between dietary K2 intake and general cardiovascular health maintenance. The published case for the three-nutrient system over a two-nutrient system is supported by large-scale human evidence. Always read the label and follow the directions for use. Vitamin and mineral supplements can only be of assistance if dietary intake is inadequate.

How much Vitamin D3 and calcium do I need daily as an Australian adult?

The NHMRC 2017 Nutrient Reference Values recommend 1,000mg of calcium daily for adults under 50, rising to 1,300mg for women over 50 and all adults over 70. For Vitamin D3, the Adequate Intake is 600 IU for adults under 70 and 800 IU for those over 70 — but these values assume average sun exposure. For indoor-working Australian adults or those in southern states during winter, most clinical guidance recommends 1,000 IU of D3 daily as a supplementation dose that supports serum 25-hydroxyvitamin D above the 50 nmol/L sufficiency threshold without approaching the 4,000 IU safe upper level. For MK-7 K2, the Knapen 2013 trial dose of 180mcg daily is the most examined research-informed target for bone mineral density support. If symptoms persist, consult your health professional.

What is the difference between calcium carbonate and calcium citrate?

Calcium carbonate requires stomach acid to dissolve and is best absorbed when taken with food, making it suitable for most adults who take their supplements with meals. It provides a higher percentage of elemental calcium per weight than citrate (40 percent versus 21 percent), meaning fewer tablets are needed to deliver the same nominal calcium dose. Calcium citrate does not require stomach acid for absorption, making it the preferred form for individuals taking proton pump inhibitors or H2 blockers, those with achlorhydria (low stomach acid, more common in older adults), or anyone who prefers to take their supplements away from meals. For most adults with normal gastric function who take their supplements with breakfast or dinner, calcium carbonate is nutritionally adequate. For older adults or those on acid-suppressing medications, calcium citrate is the superior choice.

Can I get enough Vitamin D from sunlight in Australia without supplementing?

For many Australians, the answer is no — despite living in one of the world's highest UV-index environments. The Australian Bureau of Statistics data confirms approximately one in four adults nationally is Vitamin D deficient, rising to over one in three in southern states during winter. The reasons are well-documented: indoor professional lifestyles dramatically reduce midday sun exposure; sunscreen at SPF 30+ reduces UVB-driven Vitamin D synthesis by approximately 97 per cent; darker skin requires longer UV exposure to produce equivalent D3 synthesis; and the skin's synthesis efficiency declines by approximately 75 per cent between the ages of 20 and 70. For most working Australians in temperate and southern climates, 1,000 IU of D3 daily from a TGA-listed supplement provides a safe, reliable nutritional support approach. Serum 25-hydroxyvitamin D testing through your GP provides the most definitive assessment of your individual status.

What are oxalates and phytates, and how do they affect calcium from food?

Oxalic acid — found at high concentrations in spinach, silver beet, and beetroot greens — binds calcium in the intestinal lumen to form insoluble calcium oxalate, which cannot be absorbed and is excreted. The bioavailability of calcium from raw spinach is estimated at less than 5 percent, compared to approximately 32 percent from dairy milk and approximately 21 percent from fortified soy milk. Phytic acid, concentrated in whole grains, legumes, and raw seeds, similarly chelates calcium (and zinc and iron) in the gut, reducing absorption. These compounds are partially deactivated by cooking, soaking, fermenting, and sprouting — but not eliminated. For individuals relying on plant sources for their calcium intake, the gap between nominal dietary calcium and absorbed calcium is substantially wider than food composition tables suggest, and calcium and vitamin D tablets provide a standardised, bioavailable nutritional source not subject to this interference. Vitamin and mineral supplements can only be of assistance if dietary intake is inadequate.

Are there any interactions between calcium supplements and medications?

Calcium has several clinically significant medication interactions worth discussing with your GP before initiating supplementation. Calcium reduces the intestinal absorption of levothyroxine (a thyroid medication) — a two-hour separation between calcium ingestion and levothyroxine is standard clinical guidance. Calcium chelates with certain antibiotics, particularly tetracyclines and fluoroquinolones, forming insoluble complexes that reduce antibiotic absorption — a two-hour separation is recommended. Bisphosphonate medications used to support bone health are also affected by concurrent calcium ingestion and should be taken at least 30 minutes before any food or supplements. If you take warfarin or any anticoagulant, you must discuss Vitamin K2 supplementation with your GP before initiating, as K2 is involved in coagulation factor activation and may affect anticoagulant dosing requirements. This is a mandatory advisory for Osteo+Core (AUST L 520792).

How long will it take to see results from a bone health supplement protocol?

Bone mineral density changes operate on long timelines — the Knapen 2013 MK-7 bone RCT was conducted over three years, reflecting the biological timeframe for structural bone changes to become measurable by DEXA scan. However, several functional outcomes respond faster. Muscle cramp frequency typically reduces within 30 to 60 days of supporting Vitamin D and calcium nutritional status — both are required for normal neuromuscular function. General fatigue and muscle function associated with Vitamin D insufficiency generally improve within 4 to 8 weeks of consistent D3 supplementation in previously insufficient individuals. Serum 25-hydroxyvitamin D levels can be monitored by your GP at 6 to 8 weeks to confirm that your supplementation dose is achieving the target serum concentration. The structural skeletal benefit requires a sustained 12 to 36-month commitment — which is precisely why establishing a consistent bone health nutritional protocol earlier in life builds more structural reserve before the decades of net resorption that begin after peak bone mass. Always read the label and follow the directions for use. If symptoms persist, talk to your health professional.